Skip to content

An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment

Individualized Blood Pressure Treatment: a Multidisciplinary Approach to Uncontrolled Hypertension in Order to Reduce Morbidity and Mortality

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03209154
Acronym
IDA
Enrollment
1000
Registered
2017-07-06
Start date
2017-11-01
Completion date
2025-12-31
Last updated
2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uncontrolled Hypertension

Keywords

Adherence, Therapeutic Drug Monitoring, Patient perspective

Brief summary

The aim of the study is to investigate and explore the most important aspects of drug-adherence in the treatment of hypertension in order to improve treatment and blood pressure control, implying that new knowledge will reduce morbidity and mortality.

Interventions

DIAGNOSTIC_TESTTherapeutic drug monitoring

Therapeutic drug monitoring will be performed.

Patients will perform home blood pressure monitoring at home.

Sponsors

University of Oslo
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
University Hospital of North Norway
CollaboratorOTHER
St. Olavs Hospital
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Uncontrolled hypertension * A stable medication regimen for at least 4 weeks of ≥ 2 antihypertensive agents * No planned changes in antihypertensive drugs

Exclusion criteria

* Withdrawal of consent * 24-h systolic ambulatory blood pressure \>/= 170 mmHg * Patients with inadequate Norwegian language skills * Positive pregnancy test * Known alcohol or drug abuse * estimated glomerular filtration rate \<30 mL/min/1.73m2 * Albumin/creatinin ratio \>300 mg/mmol * Any reason why, in the opinion of the investigator, the patient should not participate

Design outcomes

Primary

MeasureTime frameDescription
Blood pressure control3 months after baselineChange in systolic daytime ambulatory blood pressure.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026